excess
activ
cysteinyl
cathepsin
cysct
contribut
progress
mani
diseas
howev
therapeut
inhibit
problemat
zn
natur
inhibitor
proteas
cyshi
dyad
cyshi
xaa
triad
biguanid
form
bident
metal
complex
two
imino
nitrogen
discuss
phenformin
phenylethyl
biguanid
model
recruit
endogen
zn
inhibit
cyshiscyshi
x
peptidolysi
phenformin
zn
interact
antiproteolyt
agent
bioassay
live
tissu
benzoyllarginin
amid
baa
classic
substrat
papainlik
proteas
amid
bond
scissil
review
structur
baa
phenforminzn
complex
compar
silico
chemistri
dimens
discuss
light
activ
site
papainlik
proteas
phenyl
moieti
structur
bind
sub
keyword
cysteinyl
proteas
cysteinyl
proteas
inhibitor
zn
biguanid
pharmacophor
benzoyl
arginin
amid
substrat
abbrevi
cysteinyl
cathepsin
cyshi
cysteinehistidin
catalyt
dyad
cyshi
x
cysteinehistidin
x
amino
acid
catalyt
triad
dpap
dipeptidyl
amino
peptidas
baa
benzoyllarginin
amid
stratebind
site
typic
mani
proteas
phenyl
moieti
baa
bind
scissil
amid
bond
direct
posit
thiolateimidazolium
ion
pair
hydrolyz
howev
phenyl
moieti
phenformin
bind
coordin
zn
direct
ident
posit
catalysi
inhibit
phenformin
stabil
zn
sandwich
drug
proteas
activ
site
hundr
biguanid
deriv
synthes
nitrogen
posit
mani
conceiv
variou
substitu
moieti
regist
variou
array
substratebind
site
align
coordin
zn
catalyt
partner
divers
proteas
biguanid
identifi
modifi
pharmacophor
synthesi
therapeut
cysct
inhibitor
wide
rang
potenc
specif
introduct
pharmacolog
recruit
endogen
zn
decreas
reaction
rate
cathepsin
cyshi
dyad
cyshi
x
triad
human
genom
encod
cysteinyl
cathepsin
cysct
multipl
peptid
inhibitor
turk
et
al
cysct
serv
gener
housekeep
function
cell
type
special
role
differenti
cell
broad
substrat
accept
partial
redund
function
earli
view
cathepsin
act
within
catabol
vacuol
howev
known
cysct
function
extralysosom
extracellular
space
inactiv
oxid
natur
inhibitor
moreov
intravacuolar
reaction
rate
vari
markedli
respons
endogen
reaction
condit
despit
mammalian
complex
delet
gene
enzym
compar
wholebodi
inhibit
enzym
variou
diseas
model
compar
wildtyp
mice
delet
gene
one
cysct
see
section
delet
variou
cysct
gene
decreas
progress
divers
pathogen
process
convers
loss
endogen
proteas
inhibitor
increas
pathogen
process
optim
health
longev
requir
unexplain
balanc
cysct
activ
vs
natur
antiproteolyt
agent
pharmacolog
opposit
one
cysct
activ
might
great
therapeut
benefit
kramer
et
al
hydrolas
refer
cysteinyl
proteas
catalyt
dyad
consist
cyshi
triad
cyshi
x
x
one
sever
amino
acid
eg
asparagin
sitedirect
mutagenesi
reveal
essenti
catalyt
partner
cyshi
third
amino
acid
triad
replac
noncatalyt
amino
acid
without
loss
activ
although
chang
reaction
kinet
eg
vernet
et
al
oh
carringt
mechanist
role
third
amino
acid
triad
uncertain
centuri
investig
biochemist
standard
cyshiscyshi
x
proteas
assay
reaction
buffer
consist
metal
chelat
sulfhydryl
reduc
agent
optim
ph
standard
assay
condit
buffer
constant
maxim
reaction
rate
howev
natur
vari
vivo
reaction
cysct
wide
rang
chang
composit
endogen
reaction
buffer
machineri
regul
metal
redox
proton
cellular
compartment
level
identifi
metal
redox
proton
recogn
simultan
variabl
modul
endogen
cyshiscyshi
x
reaction
mechan
lockwood
exploit
featur
cysct
overlook
proteas
cyshiscyshi
x
catalyt
partner
share
someth
common
zn
natur
inhibitori
modul
reaction
mechan
zn
form
multident
associ
thiolat
anion
cystein
neighbor
imidazol
ring
histidin
mani
zn
finger
protein
eg
cy
zn
kochanczyk
et
al
kluska
et
al
coordin
properti
zn
cyshi
flexibl
variou
stoichiometri
stabil
found
cy
n
zn
n
bident
interact
zn
cy
thiolat
neighbor
imidazol
catalyt
site
emerg
major
compon
natur
reaction
buffer
recent
evid
suggest
cell
zn
homeostasi
interact
multipl
pathway
cell
protein
degrad
see
section
cell
content
cysct
consist
inact
zymogen
excess
ongo
proteolysi
lead
decompens
activ
proproteas
posit
feedback
necroptosi
apoptosi
see
section
lesser
excess
intracellular
extracellular
activ
gradual
injuri
mani
year
use
complet
inhibit
one
cysct
might
requir
eg
inhibit
viral
parasit
proteas
importantli
excess
inhibit
variou
proteolyt
pathway
pathogen
prolong
administr
lu
et
al
ketter
et
al
neuropath
accumul
denatur
protein
particular
concern
purpos
safe
inhibit
impli
declin
excess
activ
toward
restor
noninjuri
normal
activ
drug
could
safe
increas
antiproteolyt
effect
endogen
zn
might
lower
excess
reaction
rate
cysct
biguanid
guanylguanidin
fig
form
complex
zn
metal
cation
fig
certain
biguanid
deriv
found
zn
interact
inhibitor
proteas
reaction
enzym
assay
much
cell
protein
degrad
perfus
tissu
bioassay
sweeney
et
al
lockwood
silico
chemistri
permit
precis
comparison
small
molecul
phenformin
deriv
biguanid
biguanid
fig
benzoyllarginin
amid
baa
wellknown
artifici
substrat
divers
proteas
comparison
activ
site
papainlik
proteas
structur
baa
phenforminzn
complex
explain
one
substrat
proteas
inhibitor
zn
complex
phenformin
prototyp
design
discoveri
anti
present
analysi
involv
two
interact
proteas
activ
site
metal
complex
biguanid
deriv
interact
cyshi
cyshi
x
catalyt
partner
coordin
metal
cation
b
interact
substratebind
site
deriv
moieti
biguanid
pharmacophor
schemat
fig
much
evid
suggest
therapeut
benefit
cysteinyl
cathepsin
inhibit
review
review
excess
function
one
cysct
insuffici
one
endogen
inhibitor
contribut
multipl
diseas
perhap
normal
age
addit
intracellular
injuri
degrad
extracellular
matrix
cysct
damag
organ
system
rang
bone
vasculatur
et
al
et
al
moreov
cysct
cathepin
c
act
intracellular
convertas
activ
cocompartment
zymogen
serin
proteas
releas
inflammatori
cell
see
section
fortun
excel
review
survey
recent
progress
repetit
unnecessari
incomplet
sampl
includ
reiser
et
al
garsen
et
al
ganesan
kramer
et
al
taggart
et
al
liu
et
al
korkmaz
et
al
lowri
klegeri
larg
bodi
literatur
implic
individu
cysct
group
cysct
cysct
variou
neoplasia
howev
complex
role
lead
oppos
effect
growth
metastasi
anja
et
al
pogorzelska
et
al
much
work
remain
done
use
cysct
inhibitor
neoplasia
virus
bacteria
fungi
parasit
produc
cysteinyl
cathepsin
varieti
function
therebi
suggest
anoth
potenti
use
inhibitor
eg
lindner
et
al
sijwali
rosenth
verma
et
al
agbowuro
et
al
caffrey
et
al
mckerrow
host
cell
cysct
also
involv
infect
import
virus
eg
ebola
schornberg
et
al
brix
cysteinyl
cathepsin
inhibitor
polytherapeut
action
lowgrad
inflamm
combin
autoimmun
combin
lowgrad
inflamm
autoimmun
contribut
divers
agerel
diseas
separ
caus
multipl
cysct
variou
cell
type
underli
sever
process
requir
autoimmun
inflamm
eg
lysosom
antigen
process
cytokin
respons
activ
serin
proteas
zymogen
extracellular
degrad
etc
among
mani
fine
studi
mileston
stand
clariti
requir
cysct
inflamm
eg
guicciardi
et
al
autoimmun
eg
hsing
et
al
review
mammalian
inflamm
autoimmun
increas
zn
defici
dysregul
bonaventura
et
al
gammoh
rink
maywald
et
al
wessel
et
al
relationship
zn
dysregul
variou
cell
type
compart
b
excess
activ
one
cysct
c
elev
inflammatoryautoimmun
process
seem
like
relationship
provid
multipl
point
therapeut
intervent
b
fig
comparison
structur
benzoyllarginin
amid
baa
zn
complex
phenformin
metformin
structur
comput
fig
illustr
without
mesh
structur
phenforminzn
complex
ident
fig
regist
array
substratebind
subsit
surround
metal
sandwich
howev
drug
interact
proteas
surfac
surround
catalyt
pair
need
involv
defin
bind
pocket
mani
differ
substitu
biguanid
posit
possibl
fig
select
inhibitori
interact
depend
upon
extent
structur
chemic
complementar
substitu
proteas
surfac
potenc
inhibit
differ
properti
depend
upon
attract
vs
repuls
forc
stabil
metal
sandwich
color
figur
onlin
natur
buffer
intracellular
activ
cyshi
cyshi
x
cathepsin
submaxim
rate
regul
compon
catalyt
environ
posit
neg
control
superimpos
upon
buffer
reaction
redox
regul
metal
regul
virtual
insepar
buffer
cyshiscyshi
x
peptidolysi
ph
regul
influenc
mani
redox
interact
influenc
statu
proteas
sulfur
eg
gssg
gsh
ratio
oxygen
lockwood
dedic
lysosom
reductas
maintain
reduct
disulfid
bond
activ
cyshi
cyshi
x
cathepsin
see
rybicka
et
al
balc
et
al
allan
yate
ewanchuk
yate
addit
metal
redox
regul
vacuolar
proton
pump
vatpas
major
influenc
reaction
rate
lysosom
cysct
activ
proproteas
zymogen
hypox
acidifi
tissu
promot
increas
cysct
reaction
rate
relationship
vatpas
action
lysosom
degrad
well
known
omit
xu
ren
zn
preemptiv
decreas
cyshiscyshi
x
peptidolyt
mechan
otherwis
optim
reaction
condit
cyshi
peptidolyt
mechan
respond
rang
endogen
cell
zn
regul
intracellular
zn
sequest
protein
bind
biolog
concentr
truli
free
zn
low
known
certainti
review
discuss
thompson
fierk
concentr
free
aquo
zn
ie
six
hydrogenbond
water
molecul
suggest
rang
picomolar
howev
micromolar
cytoplasm
zn
neither
free
complet
sequest
investig
use
variou
term
refer
intermedi
form
zn
eg
mobil
activ
loos
buffer
exchang
chelat
etc
mani
form
zn
collect
refer
interact
zn
zn
exist
dynam
exchang
among
myriad
biomolecul
divers
zn
affin
eg
citrat
phosphat
certain
amino
acid
peptid
mani
sinc
zn
six
ligandbind
site
et
al
occup
two
four
site
elimin
bind
second
ligand
zn
interact
variou
molecular
structur
reaction
need
mediat
exclus
aquo
zn
case
pharmacolog
recruit
endogen
zn
inhibit
proteas
requir
precis
knowledg
biolog
concentr
aquo
zn
long
ago
studi
rate
bulk
intracellular
protein
degrad
viabl
perfus
tissu
bioassay
ie
minutetominut
releas
incorpor
cell
protein
endogen
extracellular
zn
buffer
present
perfus
much
tissu
protein
degrad
gradual
inhibit
slight
elev
extracellular
zn
concentr
without
injuri
sweeney
et
al
lockwood
contrast
approxim
bulk
cell
protein
degrad
uninhibit
supraphysiolog
zn
exposur
indefinit
suggest
cell
zn
regul
much
bulk
protein
degrad
interrel
subsequ
evid
mani
group
support
see
section
importantli
lysosom
vacuol
major
particip
cell
zn
regul
well
protein
degrad
uniqu
interact
zn
cy
thiolat
imidazol
catalyt
partner
influenc
addit
variabl
cyshiscyshi
x
peptidolysi
inactiv
oxid
proteas
sulfhydryl
divers
product
eg
ssetc
histidin
oxid
howev
signific
uncertain
mani
variabl
interact
cyshi
catalyt
partner
also
interact
independ
proteas
exampl
glutathion
interact
cyshi
proteolysi
sever
way
reduc
action
gsh
maintain
reduct
activ
proteas
sulfur
oxid
gssg
inhibit
cysteinyl
proteas
therebi
impart
sulfhydryldisulfid
redox
buffer
reaction
lockwood
gong
et
al
addit
zn
bind
properti
gsh
also
influenc
free
zn
intens
helbig
et
al
steiger
et
al
grow
evid
suggest
cell
zn
homeostasi
influenc
divers
pathway
cell
protein
degrad
vice
versa
zn
mediat
antiproteolyt
mechan
exist
beyond
catalyt
reaction
cell
zn
regul
emerg
modifi
divers
proteolyt
process
function
class
cysteinyl
proteas
includ
lysosom
proteas
calpain
caspas
deubiquitinas
interestingli
ribosom
protein
unexplain
cysteinyl
proteas
activ
unknown
function
sudhamalla
et
al
zn
found
particularli
strong
inhibitor
sever
caspas
eg
perri
et
al
subsequ
discov
zn
inhibit
multipl
caspas
mediat
zn
bind
alloster
exosit
remot
catalyt
mechan
eron
et
al
certain
viral
proteas
also
zn
bind
exosit
review
parvez
khan
calpain
inhibit
zn
activ
zn
defici
nakajima
et
al
miyoshi
et
al
zn
known
interact
ef
hand
structur
found
calpain
certain
papainlik
viral
proteas
although
proteasom
serin
proteas
report
zn
bind
site
high
affin
bind
site
presum
separ
catalyt
mechan
chouduri
et
al
zn
reportedli
induc
inhibitori
dissoci
drosophila
proteasom
subunit
kiss
et
al
interestingli
carboxyl
proteas
larg
uninhibit
interact
cell
zn
intens
metalloproteas
requir
zn
activ
zn
part
regul
lysosom
function
convers
lysosom
major
part
cell
zn
homeostasi
cell
zn
regul
includ
ion
channel
atpdepend
metal
transport
protondriven
cotransport
organ
cation
transport
oct
multidrug
toxic
transport
mate
review
hara
et
al
fukada
kamb
mikhaylina
et
al
lysosom
oppos
zn
import
export
system
vacuolar
zn
transport
serv
least
three
function
lysosom
speci
serv
zn
storag
depot
use
time
zn
insuffici
roh
et
al
b
lysosom
zn
regul
influenc
lysosom
proteolyt
function
sweeney
et
al
lockwood
c
lysosom
uptak
sequestr
exocytosi
metal
defend
cytoplasm
metal
overload
blabyhaa
merchant
kukic
et
al
sharma
et
al
protein
turnov
releas
proteinbound
zn
nutrit
defici
nutrit
avail
zn
limit
growth
metabol
prokaryot
human
sinc
cell
zn
sequest
within
protein
bulk
protein
degrad
provid
larg
zn
reservoir
releas
increas
turnov
zn
defici
induc
autophagi
releas
sequest
zn
degrad
cell
protein
investig
yeast
plant
restor
interact
cell
zn
level
promot
surviv
zn
defici
report
sever
recent
studi
eguchi
et
al
ding
zhong
hori
et
al
kawamata
et
al
nakatogawa
theori
releas
zn
degrad
protein
provid
selflimit
inhibitori
effect
brake
rate
zn
sensit
protein
turnov
futur
zn
interact
inhibitor
cyshi
catalyt
mechan
might
combin
agent
act
separ
site
proteas
site
lysosom
cellular
zn
regul
guanidin
zn
bind
ligand
neutral
ph
aoki
et
al
biguanid
bident
metal
ligand
much
greater
affin
zn
guanidin
lone
electron
pair
two
imino
nitrogen
attract
divers
metal
cation
although
affin
vari
markedli
prugnard
noel
figur
illustr
transfer
electron
densiti
bident
biguanid
ligand
zn
cation
experiment
evid
consist
structur
pharmacolog
concentr
condit
metal
dibiguanid
complex
form
central
metal
ie
biguanid
central
metal
depend
upon
characterist
particular
metal
concentr
concentr
ratio
ligand
metal
biguanidezn
format
constant
precis
known
howev
probabl
near
ie
k
edta
complet
revers
inhibitori
action
zn
zn
interact
biguanid
k
hexadent
zn
edta
complex
correspond
time
greater
affin
biguanid
stabil
biguanid
complex
variou
metal
onoff
kinet
vari
intracellular
extracellular
distribut
biguanid
among
complex
endogen
metal
speci
unknown
effect
antiproteolyt
metal
complex
need
complex
form
greatest
amount
histori
classic
proteas
substrat
benzoyllarginin
amid
late
known
papaya
plant
contain
high
amount
proteolyt
activ
review
wurtz
papain
becam
namesak
superfamili
proteas
activ
reduc
agent
inactiv
metal
cation
oxid
sulfhydryl
rawl
liu
et
al
proteas
reaction
origin
assay
crude
substrat
protein
prepar
eg
gelatin
albumin
casein
hemoglobin
order
character
hydrolysi
defin
singl
bond
variou
artifici
substrat
synthes
proteas
known
activ
toward
ester
bond
nonpeptid
amid
baa
emerg
mani
attempt
synthes
artifici
substrat
fig
amid
bond
scissil
cleavag
amid
bond
baa
assay
gener
ammonia
review
taylor
et
al
baa
surrog
substrat
divers
proteas
bergmann
et
al
greenstein
leuthardt
biochemist
blindli
screen
artifici
proteas
substrat
medicin
chemist
blindli
screen
antimalari
drug
group
unawar
relationship
emerg
separ
effort
unanticip
relationship
discov
antimalari
biguanid
deriv
antidiabet
biguanid
deriv
biguanid
synthes
long
ago
bamberg
dieckmann
biguanid
base
accept
proton
becom
charg
neutral
ph
tautomer
structur
illustr
bharatam
et
al
katritzki
et
al
complex
metal
cation
replac
ad
proton
impos
charg
metal
fig
biguanid
recogn
antihyperglycem
agent
slotta
tschesch
ignor
insulin
discov
hundr
thousand
chemic
blindli
screen
antimalari
action
multitud
chemic
variou
deriv
biguanid
found
antimalari
action
larg
number
differ
biguanid
deriv
synthes
test
describ
old
paper
patent
applic
eg
curd
et
al
curd
rose
proguanil
discov
work
fig
proguanil
wide
use
prevent
treat
malaria
combin
atovaquon
hypoglycem
side
effect
variou
biguanid
note
human
glucoselow
action
reawaken
interest
antidiabet
action
biguanid
pursuit
side
effect
led
eventu
introduct
phenformin
buformin
p
p
cyshi
p
p
proguanilzn
complex
fig
structur
proguanil
proguanilzn
complex
structur
comput
fig
without
coordin
zn
proguanil
inhibit
protein
degrad
bioassay
sweeney
et
al
cartoon
correspond
proteas
bind
site
inhibitor
structur
hypothet
approxim
sake
illustr
proguanilzn
complex
might
interact
substratebind
subsit
flank
side
catalyt
partner
howev
search
chemic
databank
biguanid
deriv
requir
inhibitori
featur
accur
unless
structur
metal
complex
account
metformin
antidiabet
usag
metformin
use
due
superior
safeti
proguanil
multipl
mechan
action
malaria
includ
antiproteolyt
action
antiparasit
action
proguanil
initi
attribut
inhibit
dihydrofol
reductas
metabolit
cycloguanil
howev
variou
biguanid
deriv
inhibit
dihydrofol
reductas
antimalari
action
convers
much
antimalari
action
proguanil
independ
antifol
effect
fidock
wellem
thu
proguanil
biguanid
drug
multipl
antimalari
mechan
inhibit
parasit
cysct
inhibit
intraerythrocyt
growth
parasit
review
sijwali
rosenth
parasit
hemoglobinolysi
result
larg
accumul
hemef
free
fe
within
erythrocyt
biguanid
bind
metal
cation
period
tabl
includ
fe
prugnard
noel
suffici
concentr
fe
alon
inhibit
cyshiscyshi
x
proteas
although
fe
much
less
potent
zn
lockwood
suggest
metformin
metalinteract
antiproteolyt
agent
might
improv
antimalari
drug
combin
lockwood
sharma
et
al
c
predict
metformin
recent
found
increas
antimalari
action
drug
oriaifo
multipl
mechan
suggest
structur
correspond
exist
among
phenformin
proguanil
chlorhexidin
fig
chlorhexidin
antibacteri
agent
wide
use
dental
practic
gingipain
secret
bacteri
cysteinyl
proteas
contribut
periodont
diseas
chlorhexidin
zn
interact
inhibitor
proteas
zn
increas
chlorhexidin
inhibit
gingipain
cronan
et
al
fig
comparison
structur
proguanil
chlorhexidin
chlorhexidin
wide
use
antibacteri
agent
chlorhexidin
zn
interact
inhibitor
bacteri
cysteinyl
proteas
known
gingipain
contribut
periodont
diseas
zn
increas
antiproteolyt
potenc
chlorhexidin
cronan
et
al
see
text
comparison
baa
phenforminmet
complex
identifi
substrat
properti
one
inhibitori
properti
without
knowledg
proteas
activ
site
structur
enzym
activ
site
known
requir
featur
inhibitor
approxim
comput
chemistri
vast
chemic
librari
search
inhibitori
candid
necessari
structur
chemic
attribut
howev
ligandprotein
model
hinder
uncertainti
surround
structur
proteas
activ
site
ligand
bind
protein
site
caus
conform
chang
particip
describ
ligandinduc
fit
principl
koshland
model
interact
rigid
ligand
rigid
bind
site
account
conform
chang
either
chemic
databank
store
inform
effect
solvent
ion
molecul
structur
ligand
bind
site
illustr
proguanil
fig
moreov
present
approach
account
intermolecular
forc
determin
ligandprotein
interact
discuss
gued
et
al
inde
ligandprotein
bind
forc
fulli
understood
model
eg
pielectron
interact
see
section
substrateinhibitor
analog
differ
ligandproteas
model
interpret
analog
known
substrat
known
inhibitor
requir
knowledg
higherord
proteas
structur
although
inform
help
phenyl
ring
baa
phenforminzn
complex
superimpos
inhibitori
metal
posit
locat
scissil
bond
conform
function
proteas
fig
analog
baa
phenfominzn
complex
relat
activ
site
structur
divers
proteas
activ
site
region
papainlik
proteas
locat
groov
cleft
valley
two
lobular
domain
illustr
cathepsin
b
sweeney
et
al
substrat
amino
acid
sequenc
regist
array
bind
site
flank
catalyt
partner
catalyt
partner
hydrolyz
peptid
bond
present
substrat
bind
orient
inhibitor
act
compet
substrat
amino
acid
bind
subsit
competit
noncompetit
b
inactiv
catalyt
reaction
c
phenforminzn
complex
simultan
interfer
substrat
bind
catalyt
mechan
fig
schechter
berger
propos
multipl
bind
pocket
subsit
correspond
multipl
substrat
amino
acid
residu
p
linear
relationship
substrat
amino
acid
sequenc
propos
bind
within
groov
domain
ie
like
bead
string
schechter
berger
review
schechter
bind
subsit
correspond
linear
sequenc
substrat
amino
acid
either
side
scissil
bond
substrat
bind
affin
orient
propos
result
combin
interact
multipl
sp
interact
one
side
catalyt
partner
inhibitor
propos
compet
substrat
peptid
bind
variou
andor
subsit
p
site
indic
amino
terminu
substrat
peptid
p
p
prime
site
indic
carboxyl
terminu
asterisk
indic
scissil
bond
h
n
p
n
p
p
p
p
p
p
p
cooh
schechterberg
concept
debat
halfcenturi
exact
posit
dimens
space
border
overlap
substrat
interact
subsit
ultim
specul
difficult
distinguish
bind
pocket
select
advantag
random
constel
amino
acid
proteas
surfac
interpret
substrat
amino
acid
sequenc
bead
string
ignor
interact
structur
proteas
substrat
inhibitor
bond
rotat
flexion
alter
sp
complementar
substrat
inhibitor
papainlik
proteas
substrat
bind
highli
specif
insofar
subsit
accept
variabl
combin
substrat
amino
acid
peptid
substrat
inhibitor
bound
variou
orient
face
bound
substrat
expos
nonselect
solvent
attract
hydrophob
exclus
schechterberg
concept
consid
oversimplif
interact
proteas
peptid
inhibitor
howev
remain
use
purpos
puzzl
substratebind
interact
share
nearli
papainfamili
proteas
one
featur
schechterberg
concept
prove
valid
mani
year
scrutini
long
ago
report
papain
one
subsit
activ
site
name
specif
interact
phenylalanin
schechter
berger
subsit
posit
sinc
confirm
major
determin
substrat
prefer
reaction
kinet
mani
proteas
turk
et
al
corvo
et
al
nearli
proteas
papain
superfamili
appear
posit
accept
bulki
hydrophob
amino
acid
eg
phenyl
moieti
baa
caspas
calpain
serin
proteas
also
seem
influenti
substratebind
posit
campbel
davi
ono
et
al
paired
et
al
interact
unexplain
puzzl
constel
amino
acid
compris
subsit
papainlik
proteas
size
boundari
variou
site
precis
defin
subsit
posit
accept
dissimilar
substrat
side
group
phenylalanin
nonspecif
hydrophob
exclus
solvent
greasi
spot
protein
surfac
provid
strong
nonselect
bind
forc
nonetheless
cysct
diverg
converg
throughout
evolut
influenc
posit
conserv
mani
mysteri
site
might
somehow
relat
pi
electron
system
phenyl
ring
see
metformin
indic
phenyl
ring
posit
unnecessari
zn
interact
inhibit
cysct
howev
interact
major
determin
potenc
metformin
phenformin
zn
interact
inhibitor
cell
protein
degrad
observ
viabl
tissu
bioassay
lockwood
drug
share
biguanid
pharmacophor
howev
dimethyl
moieti
metformin
posit
posit
complex
metal
locat
thiolat
imidazol
partner
fig
requir
antiproteolyt
concentr
metformin
tissu
bioassay
lm
approxim
time
greater
phenformin
lm
although
antiproteolyt
potenc
metformin
weak
effect
therapeut
concentr
employ
lm
supratherapeut
metformin
concentr
report
mani
experiment
action
review
found
propos
mechan
metformin
action
verifi
lm
concentr
ligandprotein
model
metformin
bind
activ
site
cathepsin
b
indic
singl
bind
mode
dimethyl
group
metforminmet
complex
bind
activ
site
mani
possibl
orient
associ
metal
share
thiolateimidazol
partner
unpublish
observ
necessari
sp
correspond
complex
metal
align
catalyt
pair
two
methyl
group
metformin
impart
partial
hydrophob
charact
complex
zn
solvent
exclus
promot
nonspecif
hydrophob
bind
metforminmet
complex
proteas
surfac
multipl
posit
immedi
surround
catalyt
pair
metal
share
thiolat
imidazol
dimethyl
moieti
metformin
pivot
multipl
bind
site
surround
proteas
surfac
without
involv
interact
sever
bind
orient
amid
proton
metformin
also
interact
electroneg
carbonyl
oxygen
peptid
backbon
illustr
phenformin
sweeney
et
al
nonetheless
differ
potenc
phenformin
metformin
suggest
interact
import
determin
bind
affin
antiproteolyt
action
interact
zn
zn
interact
drug
sulfhydrylthiolateimidazoleimidazolium
reaction
mechan
vivo
ex
vivo
reaction
condit
peptidas
esteras
nonpeptid
amidas
reaction
mechan
proteas
differ
eg
whitak
bender
other
howev
detail
ultim
specul
zn
insert
thiolat
imidazol
stop
peptidas
esteras
nonpeptid
amidas
reaction
mechan
absenc
metal
cyshiscyshi
x
peptidolyt
reaction
involv
format
thiolat
anion
imidazolium
cation
transfer
proton
illustr
berg
et
al
lone
electron
pair
nearbi
imidazol
ring
attract
proton
cystein
sulfhydryl
proton
attract
imidazol
lower
ph
sulfhydryl
ioniz
becom
nucleophil
loss
proton
sulfhydryl
transform
nucleophil
enabl
nucleophil
attack
thiolat
anion
carbonyl
carbon
peptid
bond
thiolat
anion
neighbor
imidazol
ring
exhibit
select
affin
zn
prefer
endogen
metal
speci
kochanczyk
et
al
kluska
et
al
zn
interact
catalyt
pair
involv
factor
addit
charg
metal
cation
exampl
affin
inhibitori
potenc
zn
greater
fe
howev
affin
inhibitori
potenc
zn
far
less
group
iib
cousin
cd
hg
order
magnitud
high
affin
cd
hg
suffic
titrat
concentr
cyshi
activ
site
nearli
stoichiometr
equival
absolut
valu
potenc
zn
inhibit
variou
cysct
vivo
ex
vivo
extent
metal
inhibit
strongli
depend
upon
combin
reaction
condit
purifi
cathepsin
b
inhibitori
concentr
zn
approxim
lm
mm
dtt
ph
firstli
inhibitori
action
zn
oppos
stimulatori
action
reduc
factor
includ
dtt
balc
et
al
balc
et
al
dithiol
dtt
bind
buffer
zn
thu
actual
free
zn
intens
typic
proteas
assay
less
ad
experiment
secondli
proton
compet
metal
cation
bind
site
protein
therefor
metal
inhibit
cysct
also
ph
depend
gener
zn
inhibit
cysteinyl
proteas
assay
much
greater
higher
ph
lesser
dtt
concentr
antiproteolyt
synergi
biguanid
zn
live
tissu
greater
synergi
measur
proteas
assay
perfus
tissu
bioassay
provid
reliabl
indic
antiproteolyt
potenc
variou
biguanid
deriv
standard
cysct
proteas
assay
bioassay
account
endogen
concentr
particip
influenc
format
drugzn
proteas
sandwich
exposur
phenformin
lm
requir
experiment
addit
extracellular
zn
rapid
time
cours
inhibitori
action
due
great
potenc
phenformin
acquir
suffici
intracellular
zn
maxim
antiproteolyt
action
lm
drug
concentr
contrast
antiproteolyt
action
therapeut
metformin
concentr
lm
delay
submaxim
absenc
extracellular
zn
ad
perfus
exposur
physiolog
extracellular
zn
concentr
therapeut
metformin
concentr
highli
synergist
experiment
result
expect
two
agent
similar
metalinteract
mechan
action
great
differ
bind
affin
cysct
activ
site
report
metformin
add
littl
inhibitori
action
zn
toward
proteas
assay
observ
standard
assay
condit
mm
dtt
ph
detail
describ
lockwood
contrast
phenformin
zn
synergist
ident
assay
condit
differ
among
biguanid
deriv
probabl
due
lesser
bind
affin
metforminzn
complex
proteas
conjunct
competit
dtt
zn
bind
later
found
inhibitori
synergi
metformin
zn
proteas
assay
appreci
greater
higher
ph
less
compet
dtt
concentr
unpublish
observ
therefor
therapeut
metformin
concentr
caus
zn
interact
inhibit
proteas
assay
howev
potenc
much
less
phenformin
zn
natur
influenc
mani
cellular
process
enzym
reaction
eg
kinas
conceiv
biguanid
might
inhibit
lysosom
proteolysi
indirectli
interfer
vacuolarcellular
regul
metal
ph
autophag
substrat
accumul
moreov
agent
modifi
interact
metal
biomolecul
might
multipl
effect
unrel
protein
degrad
wu
et
al
addit
action
rule
stabil
variou
drugmetalproteas
complex
combin
result
bind
biguanid
substitu
moieti
proteas
subsit
mutual
affin
biguanid
catalyt
partner
central
metal
cation
fig
simultan
zn
interact
biguanid
proteas
increas
fraction
time
catalyt
partner
occupi
zn
competit
decreas
effect
collis
substrat
bind
site
fig
bind
forc
thiolateimidazol
pair
proteas
two
imino
nitrogen
biguanid
mutual
affin
particular
metal
cation
coordin
multipl
bind
forc
attract
biguanid
substitu
moieti
proteas
surfac
surround
catalyt
partner
includ
hydrogen
bond
electrostat
charg
attract
van
der
waal
shortrang
forc
pi
electron
interact
solvent
exclus
greasi
spot
protein
surfac
ie
hydrophob
bind
absenc
metal
phenformin
competit
inhibitor
substrat
hydrolysi
cathepsin
b
proteas
assay
sweeney
et
al
substrat
bind
proteas
surfac
compet
inhibitori
zn
bind
catalyt
partner
inhibit
substrat
hydrolysi
phenforminzn
complex
theoret
involv
mix
kinet
describ
customari
michaelismenten
kinet
recent
specul
pi
system
aromat
ring
particular
interest
relat
interact
phenylalanin
site
theoret
advanc
suggest
pi
electron
system
interact
cation
anion
pi
system
solvent
meyer
et
al
schottel
et
al
dougherti
makwana
mahalakshmi
influenc
pi
electron
intermolecular
interact
old
topic
take
new
signific
phenylalanin
interact
site
could
involv
uncharacter
pi
interact
well
hydrophob
solvent
exclus
bind
forc
might
account
confus
versatil
substrat
accept
describ
howev
specul
larg
theoret
littl
experiment
basi
nonbiolog
metal
form
stabl
biguanid
associ
administ
preform
complex
bind
forc
onoff
kinet
depend
part
upon
ident
particular
metal
heterocomplex
exampl
preform
technetiumphenformin
complex
suffici
stabl
use
radiopharmaceut
imag
parenter
administr
fuk
et
al
nonbiolog
metal
speci
might
relev
medicin
applic
proteas
inhibit
eg
platinum
vanadium
chromium
iridium
paladium
nickel
technetium
lanthanum
cesium
yttrium
samarium
other
woo
et
al
patrinoiu
et
al
fuk
et
al
alsaif
refat
badea
et
al
beygzadeh
et
al
shahabadi
heidari
refat
et
al
mahmoud
et
al
chen
et
al
mihalach
et
al
metal
toxic
obviou
concern
inhibitor
specif
potenc
determin
differ
interact
proteas
activ
site
metal
specif
biguanid
inhibitor
depend
upon
uniqu
complementar
array
proteas
bind
site
activ
site
structur
multipl
proteas
almost
ident
singl
inhibitor
discrimin
accordingli
biguanid
deriv
might
coordin
inhibit
group
cysct
share
common
structur
featur
eg
et
al
inhibitori
potenc
depend
upon
combin
affin
metal
substitu
activ
site
hypothet
biguanid
deriv
uniqu
complement
bind
site
particular
proteas
high
degre
inhibitori
select
low
affin
potenc
biguanidemet
complex
low
affin
select
occupi
specif
activ
site
time
nontox
drug
concentr
adequ
long
ago
report
variou
phenylalaninecontain
structur
competit
inhibit
mammalian
cathepsin
c
fruton
mycek
mammalian
cathepsin
c
dipeptidyl
amino
peptidas
dpap
activ
particular
interest
cathepsin
c
serv
gener
protein
turnov
cell
type
et
al
cathepsin
c
also
serv
special
role
cell
mediat
inflammatori
respons
complex
structur
biolog
cathepsin
c
beyond
present
scope
see
korkmaz
et
al
seren
et
al
howev
featur
relev
polytherapeut
treatment
inflammatori
condit
perhap
parasit
infect
cathepsin
c
convertas
activ
zymogen
multipl
serin
proteas
multipl
cell
type
cathepsin
c
natur
inhibit
endogen
peptid
cystatin
f
ko
et
al
liang
et
al
proteas
present
exocyt
granul
sever
differenti
inflammatori
cell
type
pham
ley
cathepsin
c
activ
proinflammatori
serin
proteas
zymogen
exocyt
granul
eg
granzym
b
elastas
cathepsin
g
neutrophil
chymas
tryptas
mast
cell
activ
serin
proteas
releas
extracellular
space
fundament
normal
excess
inflammatori
respons
cytotox
lymphocyt
catc
knockout
mice
normal
amount
granzym
b
zymogen
proteas
retain
prodomain
remain
inact
absenc
cathepsin
c
pham
ley
extracellular
serin
proteas
variou
inflammatori
cell
involv
divers
diseas
includ
rheumatoid
arthriti
inflammatori
bowel
diseas
asthma
chronic
obstruct
pulmonari
diseas
sepsi
cystic
fibrosi
other
theori
whole
bodi
inhibitor
cathepsin
c
decreas
extracellular
action
multipl
proinflammatori
serin
proteas
releas
special
inflammatori
cell
type
guarino
et
al
impli
target
cathepsin
c
pleiotrop
bioamplifi
action
inflamm
autoimmun
et
al
major
drug
compani
current
seek
cathepsin
c
inhibitor
report
fluorogen
deriv
phearg
dipeptid
substrat
cbzpheargamc
inhibit
dpap
reaction
toward
peptid
deriv
wang
et
al
parasit
dpap
candid
antimalari
target
also
deu
deu
et
al
lehmann
et
al
would
interest
determin
whether
mammalian
parasit
dpap
might
select
sensit
biguanid
agent
structur
analog
baa
phenforminzn
complex
cathepsin
c
cathept
convertas
cathepsin
b
exodipeptidas
activ
well
endoproteas
activ
cathepsin
b
also
serv
activ
proform
variou
proteas
dysregul
cathepsin
b
implic
pathogen
activ
trypsinogen
within
pancrea
releas
digest
tract
result
pancreat
review
discuss
sendler
et
al
variou
method
synthes
biguanid
report
curd
et
al
mayer
et
al
lebel
et
al
katritzki
et
al
abba
et
al
other
biguanid
pharmacophor
low
toxic
howev
risk
deriv
must
determin
larger
biguanid
deriv
creat
selfassembl
metallosupramolecul
eg
mcmorran
et
al
mckay
et
al
presum
toxic
registri
affin
variou
deriv
moieti
multipl
subsit
creat
rang
specif
potenc
divers
proteas
coordin
inhibit
multipl
cysct
lysosom
function
might
valu
purpos
benefit
stabl
preform
biguanid
complex
nonbiolog
metal
might
exceed
risk
complet
inhibit
short
time
period
requir
eg
viral
parasit
infect
antineoplast
applic
open
question
structur
phenformin
model
appropri
relationship
phenyl
ligand
site
complex
zn
cation
catalyt
pair
mani
papainlik
proteas
fig
inhibitor
bind
subsit
presum
depend
upon
individu
structur
divers
proteas
tissu
bioassay
differ
antiproteolyt
potenc
metformin
phenformin
indic
correspond
import
determin
bind
interact
ratelimit
proteas
howev
metformin
illustr
structur
correspond
essenti
zn
interact
inhibit
protein
degrad
lesser
potenc
final
cellular
zn
regul
influenc
multipl
proteolyt
process
mechan
addit
cyshi
catalyt
mechan
metallophor
metalrel
antiproteolyt
intervent
might
discov
eg
alloster
modul
howev
present
knowledg
metalinteract
inhibit
peptidolysi
biguanid
deriv
enabl
forseeabl
discoveri
mani
new
drug
individu
cyshi
x
proteas
group
